打破常规的适应:前列腺癌无模拟MR引导立体定向消融放疗
本研究纳入15例已完成PSMA-PET/CT诊断性检查的前列腺癌患者,为每例患者分别基于PSMA-PET/CT生成无模拟计划、基于标准模拟CT生成模拟CT计划,并进行剂量学比较和流程计时。所有15例患者均成功完成无模拟流程治疗,模拟CT、无模拟与首次分次计划间剂量学差异较小且在可接受临床范围内,无模拟流程平均耗时130分钟,模拟CT流程耗时103分钟。作者结论认为该无模拟MR引导自适应放疗在前列腺SABR中可行,为消融场景下首次报道的临床经验。
要点
- 15例前列腺癌患者均成功完成无模拟MR引导SABR流程治疗。
- 模拟CT、无模拟与首次分次计划间剂量学差异较小,在可接受临床范围内,无标准化标准的主要违反。
- 无模拟流程平均耗时130分钟,模拟CT流程耗时103分钟。
核心结论
- 作者认为本研究证明了无模拟MR引导自适应放疗用于前列腺SABR的可行性和益处,为消融场景下首次报道的临床经验。
- 作者认为通过消除传统模拟扫描,该方法通过减少医院就诊次数降低患者负担并提高治疗可及性。
研究设计与样本
- 本研究纳入15例在前列腺癌诊断检查中已接受前列腺特异性膜抗原正电子发射断层扫描/CT(PSMA-PET/CT)的患者。
- 为每例患者生成两种参考计划:一种使用PSMA-PET/CT(无模拟计划),另一种使用标准模拟CT(模拟CT计划)。
- 剂量学评估包括模拟CT计划、无模拟计划与首次分次计划之间的比较。
- 进行了计时测量以评估模拟CT和无模拟治疗前流程的持续时间。
主要发现
- 所有15例患者均使用无模拟流程成功完成治疗。
- 模拟CT、无模拟与首次分次计划之间的剂量学差异较小,在可接受临床范围内,无对标准化标准的主要违反。
- 无模拟流程平均耗时130分钟,而模拟CT流程耗时103分钟。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Magnetic resonance (MR)-guided radiotherapy (MRgRT) enhances treatment precision and adaptive capabilities, potentially supporting a simulation-free (sim-free) workflow. This work reports the first clinical implementation of a sim-free workflow using the MR-Linac for prostate cancer patients treated with stereotactic ablative radiotherapy (SABR). MATERIALS AND METHODS: Fifteen patients who had undergone a prostate-specific membrane antigen positron emission tomography/CT (PSMA-PET/CT) scan as part of diagnostic workup were included in this work. Two reference plans were generated per patient: one using PSMA-PET/CT (sim-free plan) and the other using standard simulation CT (simCT plan). Dosimetric evaluations included comparisons between simCT, sim-free, and first fraction plans. Timing measurements were conducted to assess durations for both simCT and sim-free pre-treatment workflows. RESULTS: All 15 patients underwent successful treatment using a sim-free workflow. Dosimetric differences between simCT, sim-free, and first fraction plans were minor and within acceptable clinical limits, with no major violations of standardised criteria. The sim-free workflow took on average 130 min, while the simCT workflow took 103 min. CONCLUSION: This work demonstrates the feasibility and benefits of sim-free MR-guided adaptive radiotherapy for prostate SABR, representing the first reported clinical experience in an ablative setting. By eliminating traditional simulation scans, this approach reduces patient burden by minimising hospital visits and enhances treatment accessibility.
引用
- de Leon J, Jelen U, Carr M, et al. Adapting outside the box: Simulation-free MR-guided stereotactic ablative radiotherapy for prostate cancer. Radiother Oncol. 2024. PMID: 39242030. doi:10.1016/j.radonc.2024.110527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。